

Phospholipids Chiral at Phosphorus. Stereochemical Mechanism of Reactions Catalyzed by Phosphatidylinositide-Specific Phospholipase C from *Bacillus cereus* and Guinea Pig Uterus[†]

Gialih Lin,[†] C. Frank Bennett,[‡] and Ming-Daw Tsai^{*,†}

Department of Chemistry, The Ohio State University, Columbus, Ohio 43210, and Isis Pharmaceuticals Inc., 2280 Faraday Avenue, Carlsbad, California 92008

Received September 5, 1989; Revised Manuscript Received October 26, 1989

ABSTRACT: (*R*_p)- and (*S*_p)-1,2-dipalmitoyl-*sn*-glycero-3-thiophosphoinositol (DPPsI) were synthesized as a mixture and their configurations assigned on the basis of the stereospecific hydrolysis catalyzed by phospholipase A₂ (PLA2) from bee venom. PLA2 is known to be stereospecific to the *R*_p isomer of 1,2-dipalmitoyl-*sn*-glycero-3-thiophosphocholine (DPPsC) and 1,2-dipalmitoyl-*sn*-glycero-3-thiophosphoethanolamine (DPPsE). Since the configurations of (*R*_p)- and (*S*_p)-DPPsI correspond to those of (*S*_p)- and (*R*_p)-DPPsC, respectively, due to a change in priority, the isomer specifically hydrolyzed by PLA2 was assigned to (*S*_p)-DPPsI. The DPPsI analogues were then used to probe the mechanism and to elucidate the steric course of the reaction catalyzed by phosphatidylinositide-specific phospholipase C (PI-PLC) from *Bacillus cereus* and for both isozyme I and isozyme II of PI-PLC from guinea pig uterus. It was found that the *R*_p isomer of DPPsI is the preferred substrate for all three PI-PLCs. Thus PI-PLC shows the same stereospecificity as phosphatidylcholine-specific PLC (PC-PLC), which prefers the *S*_p isomer of DPPsC. The ratio of the two products inositol 1,2-cyclic phosphorothioate (cIPs) and inositol phosphorothioate (IPs) was not significantly perturbed by the use of phosphorothioate analogue for all three PI-PLCs, which implies that IPs is not produced by enzyme-mediated ring opening of cIPs and supports a parallel pathway for the formation of both products. In order to elucidate the steric course of the cyclization reaction, *exo* and *endo* isomers of cIPs were synthesized and their absolute configurations at phosphorus were determined by nuclear magnetic resonance and other techniques. It was found that *exo*-cIPs is the product produced by all three PI-PLCs. Thus the steric course of the conversion DPPsI to cIPs catalyzed by all three PI-PLCs was inversion of configuration at phosphorus. These results taken together suggest that the reaction catalyzed by PI-PLC most likely proceeds via direct attack by the 2-OH group to generate the cyclic product, and parallelly by water to generate the noncyclic inositol phosphates, without involving a covalent enzyme-phosphoinositol intermediate.

Phosphatidylinositides are important phospholipids since their metabolism is highly responsive to various extracellular stimuli acting on the cell (Michell, 1975). A key enzyme for this metabolism is phosphatidylinositide-specific phospholipase C (PI-PLC)¹ [for recent reviews see Majerus et al. (1986) and Shukla (1982)]. PI-PLC has been found in many mammalian tissues and in some bacteria. It uses phosphatidylinositol (PI), phosphatidylinositol 4-phosphate (PIP), or phosphatidylinositol 4,5-bisphosphate (PIP₂), and possibly other phosphatidylinositides as a substrate. The relative specificity of these substrates varies with the source of the enzyme, but PI is an acceptable substrate in most cases and is the substrate used

in this study. The enzyme is biologically significant since it generates three second messengers from PIP₂: diacylglycerol, inositol 1,4,5-trisphosphate, and inositol 1,2-cyclic 4,5-trisphosphate (Berridge, 1984, 1987). It is mechanistically unique in that it produces both inositol phosphates and inositol cyclic phosphates simultaneously, at a ratio dependent on the source

[†]This work was supported by Grant GM 30327 from National Institutes of Health. M.-D.T. is a Camille and Henry Dreyfus Teacher-Scholar, 1985–90. The Bruker AM-500 and MSL-300 NMR spectrometers were partially funded by NIH Grant RR 01458. This is paper 20 in the series "Phospholipids Chiral at Phosphorus". For paper 19, see Loffredo and Tsai (1990).

[‡]The Ohio State University.

^{*}Isis Pharmaceuticals Inc.

¹ Abbreviations: cIP, inositol 1,2-cyclic phosphate; cIPs, inositol 1,2-cyclic phosphorothioate; de, diastereomeric excess; COSY, correlated spectroscopy; DEPT, distortionless enhancement by polarization transfer; DPPsC, 1,2-dipalmitoyl-*sn*-glycero-3-thiophosphocholine; DPPsI, 1,2-dipalmitoyl-*sn*-glycero-3-thiophospho-1-*myo*-inositol; EDTA, ethylenediaminetetraacetate; FAB, fast atom bombardment; GC, gas chromatography; HEPES, *N*-(2-hydroxyethyl)piperazine-*N'*-2-ethanesulfonic acid; IP, inositol 1-phosphate; IPs, inositol 1-phosphorothioate; MPPsI, 1-palmitoyl-*sn*-glycero-3-thiophosphoinositol; MOMCl, chloromethyl methyl ether; MPLC, medium-pressure liquid chromatography; NOE, nuclear Overhauser enhancement; NOESY, nuclear Overhauser enhancement spectroscopy; PI, phosphatidylinositol; PIP, phosphatidylinositol 4-phosphate; PIP₂, phosphatidylinositol 4,5-bisphosphate; PI-PLC, phosphatidylinositide-specific phospholipase C; PC-PLC, phosphatidylcholine-specific PLC; PLA2, phospholipase A₂.

of the enzyme and other conditions such as pH (Dawson et al., 1971; Michell, 1975; Majerus et al., 1986, 1988).

The enzymes used in this study are PI-PLC from *Bacillus cereus* and isozyme I and isozyme II of the PI-PLC from guinea pig uterus. The *Bacillus* PI-PLC [for review see Shukla (1982); Ikezawa & Taguchi, 1986] is a metal ion independent enzyme whereas the mammalian PI-PLC requires Ca^{2+} (Majerus et al., 1986). Little mechanistic information about PI-PLC has been available. Two basic mechanistic questions for the catalysis of this enzyme are whether the reactions involve a covalent phosphoinositol-enzyme intermediate, and whether the two products are formed from a parallel or sequential pathway. We set out to probe these and other questions by the following sequence: (i) synthesis of the phosphorothioate analogues of phosphatidylinositol, (R_p+S_p)-DPPsI; (ii) assignment of their configurations; (iii) determination of the stereospecificity of PI-PLC toward DPPsI; (iv) synthesis of the two possible isomers of the cyclic product of PI-PLC, *exo*- and *endo*-cIPs; (v) elucidation of the configurations of cIPs; and (vi) elucidation of the steric course of PI-PLC. A preliminary account of part of this work (*B. cereus* enzyme only) has been published recently (Lin & Tsai, 1989).

MATERIALS AND METHODS

Materials. PI (sodium salt) from bovine liver was purchased from Avanti Polar Lipids. Bee venom PLA2 was purchased from Boehringer Mannheim. Other biochemicals were purchased from Sigma. All other chemicals were reagent grade. Silica gel used in liquid chromatography (Licorpre Silica 60, 200–400 mesh) and thin-layer chromatography (60 F₂₅₄) was obtained from EM reagent (Merck). Isozyme I [60% pure, 210 nmol/(mg·min)] and isozyme II [80% pure, 10 nmol/(mg·min)] of PI-PLC from guinea pig uterus were purified as described by Bennett and Crooke (1987). PI-PLC from *B. cereus* was purified from PLC purchased from Sigma, which contained three enzymes: PC-PLC, sphingomyelin-specific PLC, and PI-PLC (Sundler et al., 1978).

Chromatographic and Instrumental Methods. Most liquid chromatography was performed under medium pressure (ca. 20 psi) on a Licorpre silica 60 column. ¹H NMR spectra were recorded on a Bruker WM-300, AM-250, or AM-500 spectrometer. With Waltz-16 ¹H decoupling, ¹³C NMR spectra were obtained at 75.44, 62.90, and 125.76 MHz on a Bruker WM-300, AM-250, or AM-500 spectrometer, and ³¹P NMR spectra were obtained at 101.25 and 121.50 MHz on a Bruker AM-250 or WM-300 spectrometer. ³¹P chemical shifts are referenced to external 85% H₃PO₄. The ¹H and ¹³C chemical shifts are reference to external sodium 3-(trimethylsilyl)-1-propanesulfonate for D₂O samples and to Me₄Si for organic solvents. Assignments of proton chemical shifts and coupling constants were routinely assisted by homonuclear decoupling, and occasionally by other specified experiments. FAB mass spectra were recorded on a VG-70-250S mass spectrometer. Melting point was recorded on a Thomas-Hoover capillary melting point apparatus without calibration. Gas chromatography was performed on a Hewlett-Packard 5890 machine. The MM-2 energy minimization was calculated by using MODEL, CHEMX, MacroModel, or Chem 3D programs.

Synthesis of (R_p+S_p)-DPPsI. The starting compound **1** was prepared according to Garegg et al. (1984). D-1-*O*-Benzyl-4-*O*-(–)-camphanoyl-2,3:5,6-di-*O*-cyclohexylidene-*myo*-inositol (**2**) and L-3-*O*-benzyl-6-*O*-(–)-camphanoyl-1,2:4,5-di-*O*-cyclohexylidene-*myo*-inositol (**3**) were obtained from **1** according to the procedure of Billington et al. (1987). The L

form (**3**) was more polar ($R_f = 0.55$, petroleum ether–ethyl acetate, 3/1 v/v) and was obtained by recrystallization (petroleum ether–ethyl acetate, 2/1 v/v) four times from the mixture (628 mg). The D form (**2**) was less polar ($R_f = 0.62$, petroleum ether–ethyl acetate, 3/1 v/v) and was recovered from combined mother liquors by liquid chromatography on silica gel (petroleum ether–ethyl acetate, 3/1 v/v) (797 mg, 44%). D form (**2**): ¹H NMR (CDCl₃, 250 MHz) δ 7.43–7.26 (m, 5 H, phenyl of 1-*O*-benzyl), 5.36 (dd, $J_{\text{H-C}(6)\text{-C}(1)\text{-H}} = 7.0$ Hz, $J_{\text{H-C}(6)\text{-C}(5)\text{-H}} = 11.2$ Hz, 1 H, 6-H), 4.94 and 4.86 (AB, $J = 12.4$ Hz, 2 H, CH₂ of 1-*O*-benzyl), 4.36 (t, $J_{\text{H-C}(2)\text{-C}(1)\text{-H}} = J_{\text{H-C}(2)\text{-C}(3)\text{-H}} = 4.4$ Hz, 1 H, 2-H), 4.15 (dd, $J_{\text{H-C}(4)\text{-C}(5)\text{-H}} = 9.6$ Hz, $J_{\text{H-C}(4)\text{-C}(3)\text{-H}} = 10.2$ Hz, 1 H, 4-H), 4.11 (dd, $J_{\text{H-C}(1)\text{-C}(2)\text{-H}} = 4.1$ Hz, $J_{\text{H-C}(1)\text{-C}(6)\text{-H}} = 7.2$ Hz, 1 H, 1-H), 3.78 (dd, $J_{\text{H-C}(3)\text{-C}(2)\text{-H}} = 4.1$ Hz, $J_{\text{H-C}(3)\text{-C}(4)\text{-H}} = 10.3$ Hz, 1 H, 3-H), 3.38 (dd, $J_{\text{H-C}(5)\text{-C}(4)\text{-H}} = 9.4$ Hz, $J_{\text{H-C}(5)\text{-C}(6)\text{-H}} = 11.1$ Hz, 1 H, 5-H), 2.48–1.70 (m, 4 H, CH₂ of camphanoyl), 1.58–1.42 (m, 20 H, CH₂ of 2,3:5,6-di-*O*-cyclohexylidene), 1.11 (s, 3 H, camphanoyl 9-CH₃), 1.04 (s, 3 H, camphanoyl 8-CH₃), 0.99 (s, 3 H, camphanoyl 10-CH₃); ¹³C NMR (CDCl₃, 75.44 MHz) δ 178.27 (camphanoyl C-11), 166.44 (camphanoyl C-2), 137.83 (phenyl C-1 of 1-*O*-benzyl), 128.33 and 128.15 (phenyl C-3 and C-5 of 1-*O*-benzyl), 127.95 (phenyl C-2 and C-6 of 1-*O*-benzyl), 127.46 (phenyl C-4 of 1-*O*-benzyl), 113.22 (tertiary C-1 of 5,6-*O*-cyclohexylidene), 111.10 (tertiary C-1 of 2,3-*O*-cyclohexylidene) (the assignment of this resonance was made by reference to the compound containing only a 2,3-cyclohexylidene group), 91.10 (camphanoyl C-4), 76.90, 76.32, 78.25, 75.98, 75.74, 74.38, and 71.71 (CH₂ of 1-*O*-benzyl and six inositol carbons), 54.78 and 54.68 (camphanoyl C-1 and C-7), 37.50, 36.33, 36.18, and 35.20 (C-2 and C-6 of 2,3:5,6-di-*O*-cyclohexylidene); 24.91, 24.86, 23.78, 23.60, and 23.58 (C-3, C-4, and C-5 of 2,3:5,6-di-*O*-cyclohexylidene), 30.28 (camphanoyl C-6), 28.90 (camphanoyl C-5), 16.54 (camphanoyl C-9), 16.33 (camphanoyl C-8), 9.67 (camphanoyl C-10). L form (**3**): ¹H NMR (CDCl₃, 250 MHz) δ 7.36–7.20 (m, 5 H, phenyl of 1-*O*-benzyl), 5.32 (dd, $J_{\text{H-C}(6)\text{-C}(1)\text{-H}} = 7.0$ Hz, $J_{\text{H-C}(6)\text{-C}(5)\text{-H}} = 11.2$ Hz, 1 H, 6-H), 4.82 and 4.73 (AB, $J = 12.4$ Hz, 2 H, CH₂ of 1-*O*-benzyl), 4.27 (t, $J_{\text{H-C}(2)\text{-C}(1)\text{-H}} = J_{\text{H-C}(2)\text{-C}(3)\text{-H}} = 4.1$ Hz, 1 H, 2-H), 4.08 (t, $J_{\text{H-C}(4)\text{-C}(3)\text{-H}} = J_{\text{H-C}(4)\text{-C}(5)\text{-H}} = 9.8$ Hz, 1 H, 4-H), 3.97 (dd, $J_{\text{H-C}(1)\text{-C}(2)\text{-H}} = 4.9$ Hz, $J_{\text{H-C}(1)\text{-C}(6)\text{-H}} = 6.7$ Hz, 1 H, 1-H), 3.71 (dd, $J_{\text{H-C}(3)\text{-C}(2)\text{-H}} = 4.0$ Hz, $J_{\text{H-C}(3)\text{-C}(4)\text{-H}} = 10.2$ Hz, 1 H, 3-H), 3.31 (t, $J_{\text{H-C}(5)\text{-C}(4)\text{-H}} = J_{\text{H-C}(5)\text{-C}(6)\text{-H}} = 10.6$ Hz, 1 H, 5-H), 2.39 and 2.12–1.70 (m, 4 H, CH₂ of camphanoyl), 1.53–1.40 (m, 20 H, CH₂ of 2,3:5,6-di-*O*-cyclohexylidene), 1.04 (s, 3 H, camphanoyl 9-CH₃), 0.98 (s, 3 H, camphanoyl 8-CH₃), 0.93 (s, 3 H, camphanoyl 10-CH₃); ¹³C NMR (CDCl₃, 62.90 MHz) δ 178.05 (camphanoyl C-11), 166.21 (camphanoyl C-2), 137.80 (phenyl C-1 of 1-*O*-benzyl), 128.31 (phenyl C-3 and C-5 of 1-*O*-benzyl), 128.14 (phenyl C-2 and C-6 of 1-*O*-benzyl), 127.77 (phenyl C-4 of 1-*O*-benzyl), 113.30 (tertiary C-1 of 5,6-*O*-cyclohexylidene), 111.16 (tertiary C-1 of 2,3-*O*-cyclohexylidene), 91.03 (camphanoyl C-4), 78.38, 77.03, 76.31, 75.96, 75.64, 74.18, and 71.70 (CH₂ of 1-*O*-benzyl and six inositol carbons), 54.69 (camphanoyl C-1 and C-7), 37.21, 36.28, 36.20, and 35.28 (C-2 and C-6 of 2,3:5,6-di-*O*-cyclohexylidene), 24.89, 24.84, 23.78, and 23.58 (C-3, C-4, and C-5 of 2,3:5,6-di-*O*-cyclohexylidene), 30.16 (camphanoyl C-6), 28.98 (camphanoyl C-5), 16.47 (camphanoyl C-9), 16.22 (camphanoyl C-8), 9.63 (camphanoyl C-10). The % de of these two diastereomers was calculated by the relative intensities of the camphanoyl C-11 resonance from ¹³C NMR spectra under the following nonsaturating conditions: 75.44 MHz, CDCl₃, 45° pulse, and 5-s delay. The % de was also calculated by the relative intensities from the GC traces. The

% de of these products after one fractional recrystallization and one MPLC purification is about 75–90. The % de of these products after two fractional recrystallizations and two MPLC purifications is about 90–100. MS (for both isomers): m/z 610 (M^+), 397, 199, and 91.

D-1-*O*-Benzyl-2,3,5,6-di-*O*-cyclohexylidene-myo-inositol (4). A mixture of 145 mg (0.241 mmol) of **2**, 25 mL of tetrahydrofuran, 100 mg (10 equiv) of LiOH·H₂O, and 12.5 mL of water was stirred at room temperature for 25 h. To the reaction mixture were added 100 mL of dichloromethane and 100 mL of water. The organic layer was washed with 100 mL of saturated NaCl, 100 mL of saturated NaHCO₃, and 100 mL of water. The crude product was further purified by flash chromatography on silica gel (chloroform–acetone, 10/1 v/v) to give a semisolid (100 mg, 98.8% yield): TLC R_f = 0.53 (chloroform–acetone, 10/1 v/v); ¹H NMR (CDCl₃, 250 MHz) δ 7.38–7.19 (m, 5 H, phenyl of 1-*O*-benzyl), 4.82 and 4.74 (AB, J = 12.5 Hz, 2 H, CH₂ of 1-*O*-benzyl), 4.29 (t, $J_{H-C(2)-C(3)-H}$ = $J_{H-C(2)-C(1)-H}$ = 4.4 Hz, 1 H, 2-H), 3.96 (t, $J_{H-C(6)-C(1)-H}$ = $J_{H-C(6)-C(5)-H}$ = 10.0 Hz, 1 H, 6-H), 3.85 (dd, $J_{H-C(1)-C(6)-H}$ = 9.5 Hz, $J_{H-C(1)-C(2)-H}$ = 4.9 Hz, 1 H, 1-H), 3.77 (ddd, $J_{H-C(4)-C(5)-H}$ = 9.6 Hz, $J_{H-C(4)-C(3)-H}$ = 10.2 Hz, $J_{H-C(4)-O-H}$ = 2.5 Hz, 1 H, 4-H), 3.70 (dd, $J_{H-C(3)-C(2)-H}$ = 4.2 Hz, $J_{H-C(3)-C(4)-H}$ = 10.2 Hz, 1 H, 3-H), 3.18 (dd, $J_{H-C(5)-C(4)-H}$ = 9.6 Hz, $J_{H-C(5)-C(6)-H}$ = 10.1 Hz, 1 H, 5-H), 2.55 (d, $J_{H-C(4)-O-H}$ = 2.6 Hz, 1 H, OH), 1.58–1.35 (m, 20 H, CH₂ of 2,3,5,6-di-*O*-cyclohexylidene); ¹³C NMR (CDCl₃, 62.90 MHz, DL form) δ 138.08 (phenyl C-1 of 1-*O*-benzyl), 128.35 (phenyl C-2 and C-6 of 1-*O*-benzyl), 128.15 (phenyl C-3 and C-5 of 1-*O*-benzyl), 127.74 (phenyl C-4 of 1-*O*-benzyl), 113.02 (tertiary C-1 of 5,6-*O*-cyclohexylidene), 110.76 (tertiary C-1 of 2,3-*O*-cyclohexylidene), 81.35 (CH₂ of 1-*O*-benzyl), 78.21, 76.78, 76.18, 74.99, 74.76, and 71.64 (six inositol carbons), 37.78, 36.55, 36.33, and 35.18 (C-2 and C-6 of 2,3,5,6-di-*O*-cyclohexylidene), 25.01, 24.97, 23.94, 23.77, and 23.59 (C-3, C-4 and C-5 of 2,3,5,6-di-*O*-cyclohexylidene).

D-1-*O*-Benzyl-2,3,5,6-di-*O*-cyclohexylidene-4-(methoxymethyl)-myo-inositol (5). To **4** (100 mg, 0.238 mmol) in dichloromethane (25 mL), 0.96 mmol of iPr₂NEt and 0.96 mmol of MOMCl were added and the mixture was stirred at room temperature for 4.5 h. Excess MOMCl, iPr₂NEt, and solvent were removed by rotary evaporation. The crude product was purified by flash chromatography on silica gel in hexane–ethyl acetate (5/1 v/v) to give a white solid (100 mg, 90% yield): mp 110–113 °C; TLC R_f = 0.5 (hexane–ethyl acetate, 5/1 v/v); ¹H NMR (CDCl₃, 250 MHz) δ 7.45–7.26 (m, 5 H, phenyl of 1-*O*-benzyl), 4.90 and 4.78 (AB, J = 6.4 Hz, 2 H, CH₂ of 4-*O*-MOM), 4.89 and 4.82 (AB, J = 12.5 Hz, 2 H, CH₂ of 1-*O*-benzyl), 4.33 (t, $J_{H-C(2)-C(1)-H}$ = $J_{H-C(2)-C(3)-H}$ = 4.4 Hz, 1 H, 2-H), 4.10–3.88 (m, 3 H) and 3.73 (dd, J = 4.2 Hz, 10.1 Hz, 1 H) (1-H, 3-H, 4-H, and 6-H); 3.43 (s, 3 H, CH₃ of 4-*O*-MOM), 3.26 (dd, J = 10.3, 9.4 Hz, 1 H, 5-H), 1.82–0.77 (m, 20 H, CH₂ of 2,3,5,6-di-*O*-cyclohexylidene); ¹³C NMR (CDCl₃, 62.90 MHz) δ 138.08 (phenyl C-1 of 1-*O*-benzyl), 128.32 (phenyl C-2 and C-6 of 1-*O*-benzyl), 128.16 (phenyl C-3 and C-5 of 1-*O*-benzyl), 127.71 (phenyl C-4 of 1-*O*-benzyl), 112.74 (C-1 of 5,6-*O*-cyclohexylidene), 110.50 (C-1 of 2,3-*O*-cyclohexylidene), 95.20 (CH₂ of 4-*O*-MOM), 80.26, 78.01, 76.94, 76.66, 76.18, 74.56, and 71.60 (CH₂ of 1-*O*-benzyl and six inositol carbons), 55.23 (CH₃ of 4-*O*-MOM), 37.57, 36.42, and 35.33 (C-2 and C-6 of 2,3,5,6-di-*O*-cyclohexylidene), 25.04, 24.98, 23.90, 23.78, and 23.58 (C-3, C-4, and C-5 of 2,3,5,6-di-*O*-cyclohexylidene).

D-2,3,5,6-Di-*O*-cyclohexylidene-4-*O*-(methoxymethyl)-myo-inositol (6). (A) *Hydrogenolysis Method.* To **5** (100

mg, 0.215 mmol) in 40 mL of ethyl acetate was added 159 mg of 10% Pd in activated carbon at room temperature. The solution was connected to hydrogen gas (1 atm) and stirred at room temperature for 24 h. The filtrate (from Celite) was evaporated to dryness, and the product was purified by flash chromatography on silica gel in chloroform–acetone (10/1 v/v) to give 80 mg (97% yield) of white solid.

(B) *Li or Na-NH₃ Method.* To a dry tetrahydrofuran (15 mL, over Na) solution of **5** (232 mg, 0.5 mmol), Li or Na (about 160 mg) was added at –78 °C (dry ice–tetrahydrofuran bath). Dry NH₃ (over Na) was distilled into the reaction mixture and stirred at –78 °C for 1 h. To this reaction mixture, 300 mg of NH₄Cl was added at –78 °C and stirred from –78 °C to room temperature. The reaction mixture was diluted with 200 mL of petroleum ether. The organic layer was washed with 3 × 50 mL of water, 100 mL of saturated NaCl, and 100 mL of water and dried over CaCl₂. The product was purified by flash chromatography on silica gel in chloroform–acetone (10/1 v/v) to give **6** (190 mg, 100% yield): TLC R_f = 0.14 (hexane–ethyl acetate, 5/1 v/v); ¹H NMR (CDCl₃, 250 MHz) δ 4.90 and 4.78 (AB, J = 6.4 Hz, 2 H, CH₂ of 4-*O*-MOM); 4.44 (t, $J_{H-C(2)-C(1)-H}$ = $J_{H-C(2)-C(3)-H}$ = 4.7 Hz, 1 H, 2-H); 4.11 (dd, J = 5.1 Hz, J = 6.6 Hz, 1 H) and 3.94–3.79 (m, 3 H) (1-H, 3-H, 4-H, and 6-H); 3.43 (s, 3 H, CH₃ of 4-*O*-MOM); 3.31 (dd, J = 10.3, 9.4 Hz, 1 H, 5-H); 1.74–0.76 (m, 20 H, CH₂ of 2,3,5,6-di-*O*-cyclohexylidene); ¹³C NMR (CDCl₃, 62.90 MHz) δ 112.99 (C-1 of 5,6-*O*-cyclohexylidene); 110.58 (C-1 of 2,3-*O*-cyclohexylidene); 95.18 (CH₂ of 4-*O*-MOM); 80.41, 77.92, 77.24, 77.09, 77.00, and 69.98 (six inositol carbons); 55.24 (CH₃ of 4-*O*-MOM); 37.59, 36.53, 36.29, and 35.18 (C-2 and C-6 of 2,3,5,6-di-*O*-cyclohexylidene); 24.97, 24.87, 23.84, 23.76, and 23.68 (C-3, C-4, and C-5 of 2,3,5,6-di-*O*-cyclohexylidene).

1,2-Dipalmitoyl-*sn*-glycero-3-(*O*-methylthiophospho)-2,3,5,6-di-*O*-cyclohexylidene-4-*O*-(methoxymethyl)-myo-inositol (8). Compound **6** (0.47 mmol) was dried three times by rotary evaporation with 5 mL of dry toluene. To this dry compound, 5 mL of dichloromethane (dried over Na₂SO₄) and an excess of triethylamine (dried over NaH) were added through vacuum transfer. To this reaction mixture, chloro-(*N,N*-diisopropylamino)methoxyphosphine (0.70 mmol) was added through a dry syringe under the argon atmosphere. After the reaction was complete (about 25 min) on the basis of the disappearance of **6** on TLC, the solvent and excess triethylamine were removed under vacuum, and the reaction mixture was further dried in vacuo (0.2 mmHg) for 4 h. In a separate flask, thoroughly dried tetrazole (1.88 mmol) and 1,2-dipalmitoyl-*sn*-glycerol (0.56 mmol) were dissolved in tetrahydrofuran–acetonitrile (1/1 v/v) through vacuum transfer. After being warmed to 40 °C to make sure all compounds were dissolved, the solution was added to the above reaction mixture by a syringe under argon. After stirring for 18 h at room temperature, the reaction was complete on the basis of TLC. The solvents were evaporated to dryness and replaced with 10 mL of dry toluene (distilled over NaH). To this heterogeneous mixture, an excess of S₈ (powder, sublimed) was added at room temperature. The suspension was stirred at room temperature for 2 days. The reaction mixture was then washed with 25 mL of saturated NaHCO₃, and the organic phase was evaporated to dryness. The crude product was purified by liquid chromatography on silica gel in dichloromethane–diethyl ether (95/5 v/v) to give **8** (an oil, 405 mg, 83% yield from **6**): TLC (dichloromethane–diethyl ether, 95/5 v/v) R_f = 0.7; ¹H NMR (CD₃OD, 250 MHz) δ 5.24 (m, 1 H, glycerol-*sn*-2-CH); 4.88 and 4.76 (AB, J = 6.4 Hz, 2 H,


CH₂ of 4-*O*-MOM); 4.82 and 4.35 (m, 2 H, glycerol-*sn*-1 CH₂); 4.52 (dd, $J = 4.5, 9.0$ Hz, 1 H, 1-H); 4.26–3.99 (m, 4 H, 4-H, 6-H, and glycerol-*sn*-3 CH₂); 3.81 and 3.75 [two doublets, $^3J_{P-H} = 5.2$ Hz, 3 H, (*R*_p)- and (*S*_p)-POCH₃]; 3.36 (t, $J = 10.2$ Hz, 1 H, 5-H); 2.31 (t, $J = 7.5$ Hz, 2 H, α -CH₂ of *sn*-2 acyl chain); 2.28 (t, $J = 7.4$ Hz, 2 H, α -CH₂ of *sn*-1 acyl chain); 1.60 (m, 4 H, acyl chain β -CH₂); 1.8–1.1 (m, 72 H, all the other CH₂ protons); 0.86 [t, $J = 7.4$ Hz, 6 H, acyl-chain 16(t)-CH₃]. The above assignments were made in reference to **6**, PI (Shibata et al., 1984), and 1,2-dipalmitoyl-*sn*-glycerol-3-phosphocholine (Hauser et al., 1980), and by ³¹P decoupling. ¹³C NMR (CD₃OD, 62.90 MHz) δ 173.14 and 172.71 (acyl chain C=O); 113.20 and 110.77 (tertiary C-1 of 2,3:5,6-di-*O*-cyclohexylidene); 95.15 (CH₂ of 4-*O*-MOM); 80.31, 75.94, 75.65, 75.58, 75.09, and 74.99 (six inositol carbons); 69.15 (glycerol-*sn*-2); 65.51 (glycerol-*sn*-3); 61.81 (glycerol-*sn*-1); 55.24 (CH₃ of 4-*O*-MOM); 54.76 and 54.44 (dd, $^2J_{POC} = 6.9$ Hz, POCH₃); 37.55, 36.33, 36.12, and 35.15 (C-2 and C-6 of 2,3:5,6-di-*O*-cyclohexylidene); 34.15 (α -CH₂ of *sn*-2 acyl chain); 34.00 (α -CH₂ of *sn*-1 acyl chain); 31.68 (acyl chain 14-CH₂); 29.63, 29.43, 29.30, 29.24, and 29.08 (acyl chain 4-13 CH₂); 24.88, 23.87, 23.78, and 23.56 (C-3, C-4, and C-5 of 2,3:5,6-di-*O*-cyclohexylidene); 24.81 (acyl-chain β -CH₂); 22.63 (acyl-chain 15-CH₂); 14.04 (acyl-chain t-CH₃). ³¹P NMR (CD₃OD, 101.26 MHz) showed two diastereomers: δ 67.93, 67.63. Two minor resonances arising from the L form of the inositol moiety was also detected by ³¹P NMR (67.86 and 67.69 ppm).

(*R*_p+*S*_p)-DPPsI (**9**). To 110 mg of **8** were added 4 mL of tetrahydrofuran and 2 mL of 6 N HCl. The resulting solution was stirred at room temperature for 3 h. Solvents and HCl were removed by rotary evaporation. To this dry solid, toluene (over NaH, 10 mL) and anhydrous trimethylamine (over NaH, 5 mL) were added through vacuum transfer. The resulting solution was stirred at room temperature for 15 h. After the deprotection reaction was complete, the mixture was evaporated to dryness and dissolved in 100 mL of chloroform. The organic layer was washed with 3 \times 50 mL of saturated NaCl and was concentrated to about 1 mL. This compound was purified by liquid chromatography on silica gel with chloroform–methanol (2/1 v/v) as the eluting solvent to give 62.4 mg of a white solid **9** (73% yield): TLC $R_f = 0.2$ (chloroform–methanol–H₂O, 66/33/4 v/v/v); ¹H NMR (500 MHz, CD₃OD–CDCl₃, 1/2 v/v) δ 5.25 (m, 1 H, *sn*-2 CH); 4.41 and 4.19 (m, 2 H, glycerol-*sn*-1 CH₂); 4.23–4.09 (m, 4 H, 2-H, glycerol-*sn*-3 CH₂ and 1-H); 3.78 (m, 1 H, inositol 6-H); 3.59 (m, 1 H, inositol 4-H); 3.42 (m, 1 H, inositol 3-H); 3.25 (m, 1 H, inositol 5-H); 2.31 (t, $J = 7.4$ Hz, 2 H, α -CH₂ of *sn*-2 acyl chain); 2.29 (t, $J = 7.4$ Hz, 2 H, α -CH₂ of *sn*-1 acyl chain); 1.58 (m, 4 H, acyl-chain β -CH₂); 1.26 (b, 48 H, all the other CH₂ protons); 0.86 (t, $J = 7.4$ Hz, 6 H, acyl-chain t-CH₃); ¹³C NMR (CD₃OD, 125.76 MHz) δ 173.43 and 173.13 (acyl chain C=O); 76.53 (inositol C-1); 73.91 (inositol C-5); 71.92 (inositol C-4); 71.16 (inositol C-6); 70.91 and 70.78 (inositol C-2); 70.70 (inositol C-3); 69.94 and 69.85 (glycerol-*sn*-2); 63.61 and 63.34 (glycerol-*sn*-3); 62.13 (glycerol-*sn*-1); 33.51 (acyl-chain *sn*-2 α -CH₂); 33.39 (acyl-chain *sn*-1 α -CH₂); 31.19 (acyl-chain 14-CH₂); 28.96, 28.79, 28.62, and 28.45 (acyl-chain 4–13 CH₂); 24.19 (acyl-chain β -CH₂); 21.91 (acyl-chain 15-CH₂); 12.96 (acyl-chain t-CH₃). The assignments of ¹³C NMR spectrum were made by the ¹H/¹³C COSY spectrum and by ¹³C DEPT spectra (Lin, 1989). ³¹P NMR (CD₃OD–CDCl₃, 1/2 v/v, 101.26 MHz) δ 55.934, 57.01. Two minor peaks were observed at δ 56.35 (possibly due to the contaminating L form) and 57.88 (possibly due to 1,2-mi-

gration). Detailed assignments in a different solvent have been described in the text. MS (FAB) m/z 850 ([M + Na + H]⁺), 849 ([M + Na]⁺), 551 (dipalmitoylglycerol – OH), 331 (inositol phosphorothioate + C₃H₅O), 315 (*O*-vinyl inositol phosphorothioate diester), 275 (inositol phosphorothioate), and 179 (inositol – H). The above assignments of MS fragments were made in reference to PI (Jugalwala, 1985; Jensen, 1987).

Hydrolysis by PI-PLC. The hydrolysis of DPPsI by *B. cereus* PI-PLC was followed by ³¹P NMR as described in the legend of Figure 2. The hydrolysis of DPPsI by guinea pig uterus PI-PLC was followed similarly except for the presence of 3 mM deoxycholate, using 3 mg of substrate and 3.5 mg of enzyme in 1 mL of buffer in the case of isozyme I, and 1 mg of substrate and 2.4 mg of enzyme in 1 mL of buffer in the case of isozyme II. The reaction time was 3 days at room temperature. No quantitative kinetic data were obtained, but the reactivity of DPPsI is estimated to be <1% relative to the natural PI. In all cases ca. 50% of the *R*_p isomer was consumed in 3–4 days. As a control, we have shown that *exo*-cIPs (**18a**) incubated under identical conditions except the absence of PI-PLC gave no detectable ring-opened product IPs by ³¹P NMR.

Synthesis of myo-Inositol 1,2-Cyclic Phosphorothioates. DL-*exo*-3,4,5,6-Tetra-*O*-benzyl-*myo*-inositol 1,2-Cyclic *O*-Methylphosphorothioate (**17a**) and DL-*endo*-3,4,5,6-Tetra-*O*-benzyl-*myo*-inositol 1,2-Cyclic *O*-Methylphosphorothioate (**17b**). **13** (0.156 mmol) [prepared by the procedures of Ozaki et al. (1986)] was dried three times by rotary evaporation with 2 mL of dry toluene. To this dry material, 5 mL of dichloromethane (over Na₂SO₄) and an excess of triethylamine (over NaH) were added through vacuum transfer. While the mixture was still cold, chloro(*N,N*-diisopropylamino)methoxyphosphine (1.25 equiv, 0.195 mmol) was added to the flask through a dry syringe. The reaction was completed about 30 min later on the basis of TLC, and the solvent and excess triethylamine were removed under vacuum. The reaction mixture was further dried in vacuo (0.01 mmHg) for 1/2 h. Thoroughly dried tetrazole (4 equiv, 0.624 mmol, Aldrich gold label) was dissolved in tetrahydrofuran–acetonitrile (1/1 v/v, 20 mL, over NaH) through vacuum transfer. After being warmed to 40 °C to make sure all compounds were dissolved, this solution was added to the above reaction mixture through a syringe under the argon atmosphere. The reaction mixture was stirred at room temperature for 4 h and then evaporated to dryness. To this mixture, 50 mL of dry toluene (dried over NaH) and an excess of S₈ (powder, sublimed) were added at room temperature. The suspension was stirred at room temperature for 6 days. The reaction mixture was then washed with 25 mL of saturated NaHCO₃ and evaporated to dryness. The crude products were purified by MPLC on silica gel in hexane–ethyl acetate (5/1 v/v) to give an oil, **17a** [5 mg, 5% yield based on **13**; TLC $R_f = 0.31$ (hexane–ethyl acetate (5/1 v/v))] and an oil **17b** [42 mg, 60% yield based on **13**; TLC $R_f = 0.26$ (hexane–ethyl acetate, 5/1 v/v)]. Procedures and rationales for configurational assignments of the two isomers are described in the text. Detailed proton resonance assignments were made in reference to cIP (Cerdan et al., 1986), and by ¹H–¹H decoupling experiments, ³¹P decoupling ¹H NMR, 2-D *J*-resolved ¹H NMR, and 2-D NOESY. **17a** (*exo*): ³¹P NMR (CDCl₃, 101.256 MHz) δ 84.41; ¹H NMR (CDCl₃, 500 MHz) δ 7.35–7.24 (m, 20 H, phenyl of 3,4,5,6-tetra-*O*-benzyl); 4.87 (ddd, $J_{H-C(2)-C(1)-H} = 6.5$ Hz, $J_{H-C(2)-C(3)-H} = 4.0$ Hz, $^3J_{P-O-C(2)-H} = 3.7$ Hz, 1 H, 2-H); 4.85 and 4.75 (AB, $J = 11.2$ Hz, 2 H, CH₂ of 6-*O*-benzyl); 4.76 and 4.70 (AB, $J = 11.0$ Hz, 2 H, CH₂ of 5-*O*-benzyl); 4.77

Scheme I: Synthesis and Reactions of DPPsI^a

^a Reagents and conditions: (a) (-)-camphoric acid chloride, Et₃N, DMAP, CH₂Cl₂, 25 °C, 7 h; (b) LiOH, THF-H₂O (2:1), 25 °C, 2 h; (c) CH₃OCH₂Cl, iPr₂NEt, CH₂Cl₂, 25 °C, 17 h; (d) H₂/10% Pd-C, or Li, THF-NH₃, -78 °C, 1/2 h; (e) ClP(OCH₃)N(iPr)₂, Et₃N, CH₂Cl₂, 25 °C, 1/2 h; (f) (i) 1,2-dipalmitoyl-*sn*-glycerol, tetrazole, THF-CH₃CN, 25 °C, 24 h; (ii) S₈, toluene, 25 °C, 47 h; (g) (i) 80% HOAc, 90–100 °C, 2–3 h; (ii) NMe₃, toluene, 25 °C, 15 h; (h) PLA2; (i) PI-PLC.

and 4.69 (AB, *J* = 11.0 Hz, 2 H, CH₂ of 3-*O*-benzyl); 4.68 and 4.66 (AB, *J* = 11.0 Hz, 2 H, CH₂ of 4-*O*-benzyl); 4.59 (ddd, *J*_{H-C(1)-C(2)-H} = 6.3 Hz, *J*_{H-C(1)-C(6)-H} = 8.1 Hz, ³*J*_{P-O-C(1)-H} = 18.4 Hz, 1 H, 1-H); 4.20 (dd, *J*_{H-C(6)-C(5)-H} = 9.7 Hz, *J*_{H-C(6)-C(1)-H} = 7.9 Hz, 1 H, 6-H); 3.86 (dd, *J*_{H-C(4)-C(3)-H} = 7.3 Hz, *J*_{H-C(4)-C(5)-H} = 7.1 Hz, 1 H, 4-H); 3.76 (d, ³*J*_{P-O-C-H} = 15.0 Hz, 3 H, CH₃OP); 3.73 (dd, *J*_{H-C(3)-C(4)-H} = 7.5 Hz, *J*_{H-C(3)-C(2)-H} = 3.9 Hz, 1 H, 3-H); 3.45 (dd, *J*_{H-C(5)-C(6)-H} = 9.7 Hz, *J*_{H-C(5)-C(4)-H} = 7.0 Hz, 1 H, 5-H). **17b** (endo): ³¹P NMR (CDCl₃, 101.256 MHz) δ 82.65; ¹H NMR (CDCl₃, 500 MHz) δ 7.44–7.22 (m, 20 H, phenyl of 3,4,5,6-tetra-*O*-benzyl); 4.92 and 4.82 (AB, *J* = 11.1 Hz, 2 H, CH₂ of 6-*O*-benzyl); 4.83 and 4.73 (AB, *J* = 12.2 Hz, 2 H, CH₂ of 3-*O*-benzyl); 4.79 and 4.71 (AB, *J* = 11.1 Hz, 2 H, CH₂ of 5-*O*-benzyl); 4.73 (ddd, *J*_{H-C(2)-C(1)-H} = 6.6 Hz, *J*_{H-C(2)-C(3)-H} = 3.4 Hz, ³*J*_{P-O-C(2)-H} = 5.5 Hz, 1 H, 2-H), 4.60 (ddd, *J*_{H-C(1)-C(2)-H} = 6.6 Hz, *J*_{H-C(1)-C(6)-H} = 8.2 Hz, ³*J*_{P-O-C(1)-H} = 9.7 Hz, 1 H, 1-H); 4.56 (s, 2 H, CH₂ of 4-*O*-benzyl); 4.35 (dd, *J*_{H-C(6)-C(5)-H} = 10.0 Hz, *J*_{H-C(6)-C(1)-H} = 7.8 Hz, 1 H, 6-H); 3.87 (dd, *J*_{H-C(4)-C(5)-H}

= 6.3 Hz, *J*_{H-C(4)-C(3)-H} = 5.3 Hz, 1 H, 4-H); 3.85 (d, ³*J*_{P-O-C-H} = 14.6 Hz, 3 H, CH₃OP); 3.76 (dd, *J*_{H-C(2)-C(3)-H} = 3.2 Hz, *J*_{H-C(4)-C(3)-H} = 5.7 Hz, 1 H, 3-H); 3.46 (dd, *J*_{H-C(5)-C(6)-H} = 10.2 Hz, *J*_{H-C(5)-C(4)-H} = 6.6 Hz, 1 H, 5-H).

DL-*exo*-cIPs (18a) and DL-*endo*-cIPs (18b). To a dry tetrahydrofuran (2 mL, over Na) solution of **17a** (14 mg, 0.022 mmol) was added Li (12 mg, 60 equiv) at -78 °C (dry ice-tetrahydrofuran bath). Dry NH₃ (over Na) was distilled into the above reaction mixture. After stirring at -78 °C for 5 min, 3 mg of NH₄Cl was added at -78 °C. The reaction mixture was stirred while warming up from -78 °C to room temperature and dissolved in 2 mL of D₂O. ³¹P NMR (D₂O, 101.256 MHz) δ 69.85. **18b** was prepared by the same procedure in 60% yield from **17b**. ³¹P NMR (D₂O, 101.256 MHz) δ 69.00.

RESULTS

Synthesis of DPPsI. DPPsI was synthesized according to Scheme I. The overall procedure is novel and should be applicable to future synthesis of labeled or unlabeled phos-

phatidylinositides. However, most of the individual steps have been adopted from known procedures established for related systems. The starting compound **1**, DL form of a protected *myo*-inositol, was synthesized from *myo*-inositol as described by Garegg et al. (1984). Resolution of D and L enantiomers was achieved by derivatization with (-)-camphanic acid chloride followed by chromatographic separation of **2** and **3** (Billington et al., 1987; Vacca et al., 1987). The D form **2** was obtained in >99% diastereomeric excess (de) on the basis of gas chromatographic analysis. However, for practical reasons, the % de of the bulk sample of **2** used in the synthesis of DPPsI varied between 75 and 90%. The camphanyl group in **2** was then removed by basic hydrolysis, which yielded **4** in quantitative yield. Protection of **4** with chloromethyl methyl ether (MOMCl) (Corey et al., 1982a,b; Stork & Takahashi, 1977) gave **5** in 90% yield. Debenzylation of **5** was achieved quantitatively by hydrogenolysis on 10% Pd-C, or by reductive debenzylation with Li or Na metal in tetrahydrofuran and liquid NH₃, a procedure modified from Potter and Lowe (1981). The product **6** has the correct OH group open for phosphorylation.

The phosphorylation steps were adapted from Bruzik et al. (1986). Thus, phosphitylation of **6** with chloro(*N,N*-diisopropylamino)methoxyphosphine gave phosphoramidite **7**. This phosphoramidite was condensed with 1,2-dipalmitoyl-*sn*-glycerol in the presence of tetrazole to give a phosphite triester intermediate, which was sulfurized with an excess of S₈ to give a phosphorothioate triester **8**, which is the precursor of DPPsI. The overall yield from **6** to **8** was 83%. The presence of two diastereomers of **8** was identified by two equal-intensity resonances in ³¹P NMR at 67.63 and 67.93 ppm. Deprotection of two ketal groups and the methoxymethyl ether by acid hydrolysis, followed by demethylation with trimethylamine, gave (*R_p*+*S_p*)-DPPsI (**9**) in 73% yield. The presence of two diastereomers was characterized by two resonances in ³¹P NMR at 55.71 and 55.32 ppm, as shown in Figure 1A. The pair of small peaks (55.56 and 55.40 ppm) labeled as a and b, respectively, can be attributed to DPPsI in which the configuration of the inositol moiety is L instead of D, since the intensity of these two peaks corresponds with the % de of **2**. A similar ³¹P NMR pattern (two major peaks due to D form, two minor peaks due to L form) was also observed for the precursor **8** as described under Materials and Methods. Besides those peaks, two small peaks at 57.13 and 57.02 ppm (10–15%) in ³¹P NMR were also observed (not shown), which were attributed to the products of 1,2-migration of the phosphatidyl moiety during the last acid deprotection step, since no such impurity was observed in the precursor **8**. To further confirm such an interpretation, we have found that treatment of commercial PI (12 mg in 0.6 mL of CDCl₃) (³¹P δ 5.31 ppm) with concentrated HCl resulted in the formation of a new peak at 7.71 ppm. These two isomeric impurities (<15% in each case) were not separated from DPPsI. However, they presented no problem to the spectral assignments and the biochemical studies of DPPsI.

Configurational Assignment of DPPsI by Phospholipase A₂. It has been established previously that phospholipase A₂ (PLA₂) from various sources specifically hydrolyzes the *R_p* isomer of phosphorothioate analogues of phosphatidylcholines and phosphatidylethanolamines (Orr et al., 1982; Bruzik et al., 1982, 1983; Jiang et al., 1984). Since PLA₂ has a broad specificity toward different types of phospholipids, it can be used to assign the absolute configuration at phosphorus of DPPsI. It should be noted that, due to a change in priority, the relative configurations of (*R_p*)- and (*S_p*)-DPPsI correspond




FIGURE 1: Use of ³¹P NMR to monitor the hydrolysis of DPPsI by PLA₂. (A) 10 mg of (*R_p*+*S_p*)-DPPsI in 50% D₂O containing 5% Triton X-100, 50 mM HEPES buffer, pH 7.2, 2.5 mM Ca²⁺, and 0.25 mM EDTA. (B) Spectrum taken within the first 30 min after addition of 1.3 mg of PLA₂ from bee venom. (C) After further incubation at 25 °C for 12 h.

to those of *S_p* and *R_p* isomers, respectively, of DPPsC. As shown in Figure 1B, upon addition of bee venom PLA₂ to DPPsI, the downfield peak of ³¹P resonances of DPPsI (55.71 ppm) disappeared and was thus assigned to (*S_p*)-DPPsI. The resonance of the product (*S_p*)-MPPsI (**10**) happened to coincide with that of (*R_p*)-DPPsI (**11**) (55.32 ppm). These assignments have been verified by independent experiments in which hydrolysis of (*S_p*)-DPPsI was only partially complete. The small peak c in Figure 1B can be attributed to the product from b, since PLA₂, being insensitive to the type of the head group, is not expected to be sensitive to the configuration of the inositol ring. Such interpretation also yields assignment of a and b as *R_p* and *S_p* isomers, respectively. The less reactive isomer (*R_p*)-DPPsI can also be hydrolyzed by PLA₂ upon further incubation, as shown in Figure 1C.

Hydrolysis of DPPsI Catalyzed by PI-PLC. It has been shown that PC-PLC specifically hydrolyzes the *S_p* isomers of DPPsC and DPPsE (Orr et al., 1982; Bruzik et al., 1982, 1983; Jiang et al., 1984). Bruzik (1988) also observed that PLC also specifically hydrolyzed one isomer of the phosphorothioate analogues of sphingomyelin. As shown in Figure 2A,B, the PI-PLC from *B. cereus* stereospecifically converts the *R_p* isomer of DPPsI to the product, cIPs at 69.89 ppm in ³¹P NMR. Thus PI-PLC shows the same stereospecificity as PC-PLC despite the differences in structural and catalytic properties. Unlike PI-PLC from mammalian sources, the *Bacillus* enzyme gives only cyclic IP according to Michell




FIGURE 2: Use of ^{31}P NMR (101.2 MHz) to show the stereospecificity of PI-PLC. (A) 7.5 mg of (R_p+S_p)-DPPsI in 50% D_2O containing 5% Triton X-100, 50 mM HEPES buffer, pH 7.2, 2.5 mM Ca^{2+} , and 0.25 mM EDTA. (B) 72 h after addition of 2 mg of PI-PLC from *B. cereus*. (C) **18a** (*exo*-DL-cIPs). (D) **18b** (*endo*-DL-cIPs).

(1975). This was confirmed by our ^{31}P NMR analysis, which showed no detectable noncyclic product from either the natural PI or the synthetic DPPsI.

Essentially the same results were obtained for both isozyme I and isozyme II of the PI-PLC from guinea pig uterus, except that an additional noncyclic product IPs at 43.84 ppm was observed in both cases. On the basis of relative intensities, it can be concluded that the R_p isomer of DPPsI is the precursor for both cIPs and IPs. The ratio cIPs/IPs was ca. 2 for isozyme I and ca. 0.5 for isozyme II as determined by ^{31}P NMR. Separate ^{31}P NMR experiments using natural PI as substrate showed that the ratio cIP/IP was 1 for isozyme I and 0.5 for isozyme II. Thus the use of phosphorothioate analogue does not have a significant effect on the ratio of the two products. The mechanistic implication of this finding will be discussed later.

Synthesis of Inositol 1,2-Cyclic Phosphorothioate (cIPs). In order to elucidate the steric course of the reaction, it is necessary to determine the configuration of the product. Since





FIGURE 3: Structures of model phosphites **19a** and **19b** and products of sulfurization **20a** and **20b**.

only one isomer of cIPs is generated and the quantity is very limited from enzymatic reactions, we set out to synthesize both isomers of cIPs according to Scheme II. The tetrabenzylated *myo*-inositol **13** was first prepared from established procedures (Angyal et al., 1961; Gigg & Warren, 1969; Watanabe et al., 1987). Monophosphitylation with 1.2 equiv of chloro(*N,N*-diisopropylamino)methoxyphosphine in the presence of 1.5 equiv of triethylamine gave phosphoramidites **14** and **15**. After removal of the excess triethylamine, 4 equiv of tetrazole in tetrahydrofuran-acetonitrile was added to the reaction mixture to form two cyclic phosphite triesters **16a** and **16b**. This procedure affords a novel and efficient synthesis of 1,3,2-dioxaphospholanes. These phosphite triesters were oxidized by elemental sulfur (S_8) to give **17a** and **17b**, which were separated by medium-pressure liquid chromatography and resulted in 5 and 60% yield, respectively, based on **13**. Deprotection of **17a** and **17b** with Li metal in tetrahydrofuran-liquid NH_3 at -78°C for 5 min [modified from Potter and Lowe (1981)] gave the two isomers of cIPs **18a** and **18b**, respectively. It is believed that the benzyl groups are removed by a radical reductive cleavage and the methyl group is removed by an $\text{S}_{\text{N}}2$ nucleophilic attack of ammonia; neither would affect the configuration at phosphorus. However, it is important that the reaction time is kept within 5 min; otherwise ring opening and desulfurization products may dominate. It should be noted that throughout the above synthesis DL mixtures were used since it will have no effect on chemical shifts.

The two isomers of DL-cIPs have also been synthesized by Schultz et al. (1988) by a different procedure which gave lower yield (20%). In addition, Schultz et al. (1988) have not assigned the absolute configurations of cIPs. Our configurational analysis is described in the next section.

Configurational Assignment of cIPs. The phosphorus configurations of **18a** and **18b** were not assigned directly. Instead, they were derived from their precursors **17a** and **17b**, respectively. The absolute configuration at phosphorus of **17a** and **17b** was assigned on the basis of the following four criteria:

(1) It has been well established that the predominant conformation of the phosphite **19** in Figure 3 is the sterically less hindered trans form, **19b** (McEven, 1965; Denney et al., 1969; Bentrude & Tan, 1976). As also shown in Figure 3, oxidation (or sulfurization) of phosphite is known to proceed with retention of configuration at phosphorus; moreover, the *cis/trans* ratio of phosphite was the same as that of the resulting product

Scheme II: Synthesis of *exo*- and *endo*-cIPs^a

^aOnly D-forms are shown. Reagents and conditions: (a) 1.2 equiv of CIP (OCH₃)N(iPr)₂, iPr₂NEt, CH₂Cl₂, 25 °C, 1/2 h; (b) 4 equiv of tetrazole, THF-CH₃CN, 25 °C, 18 h; (c) excess S₈, toluene, 25 °C, 48 h; (d) 40 equiv of Li, THF-NH₃, -78 °C, 5 min.

(McEwen, 1965; Denney et al., 1969; Bentruide & Tan, 1976; Mikolajczyk et al., 1976; Mikolajczyk & Witczak, 1977). Since the yield of 17b (60%) is larger than that of 17a (5%), 17b should correspond to 20b (and 16b should correspond to 19b). Our MM-2 calculation also confirmed that 16b (minimization energy 85.3 kcal/mol) is more stable than 16a (88.5 kcal/mol). The configuration of 17b can thus be established as *endo* (*D*-S_p + *L*-R_p), and that of 17a as *exo* (*D*-R_p + *L*-S_p). It should be noted that in all the "b" series the OCH₃ group is located opposite to the other substituents on the five-membered 1,3,2-dioxaphospholanes ring, but the isomeric notation varies from compound to compound.

(2) The second evidence supporting these assignments was derived from the chemical shift difference in the ³¹P NMR spectra. In ³¹P NMR, the *trans* isomer 20a resonates more downfield than the *cis* isomer 20b by 0.5–2.5 ppm (Mikolajczyk et al., 1976; Mikolajczyk & Witczak, 1977). The ³¹P resonances observed for 17a and 17b (84.41 and 82.65 ppm, respectively) are consistent with this qualitative trend.

(3) The assignments were further confirmed by the three-bond coupling constants between P and 1-H. The relationship between ³J_{P-O-C-H} and the P-O-C-H dihedral angle (φ) can be written as (Bentruide & Setzer, 1987)

$${}^3J_{\text{POCH}} = 15.3 \cos^2 \phi - 6.1 \cos \phi + 1.6 \quad (1)$$

According to the structures after MM-2 energy minimization [the bond angle and length data were obtained from Mikolajczyk et al. (1976) and Cerdan et al. (1986)], the H-C-(1)-O-P dihedral angles of 17a and 17b were 150° and 124°,

respectively. The *J*_{H-C(1)-O-P} values calculated from eq 1 are 18.3 and 9.8 Hz for 17a and 17b, respectively, which agree very well with the observed values (18.4 and 9.7 Hz, respectively).


(4) The fourth evidence that supports these assignments is based on the analysis of the NOESY spectra of 17a and 17b (panels A and B, respectively, of Figure 4). In 17a but not in 17b, a detectable NOE is observed between 4-H and the *O*-methyl proton resonance, which suggests that the *O*-methyl group is at the same side with the 4-H of the inositol ring in 17a and supports the assignment of *exo* to 17a. On the other hand, in 17b but not in 17a, a detectable NOE is observed between 2-H and the *O*-methyl proton resonance. This suggests that the *O*-methyl group is at the same side with the 2-H of the inositol ring in 17b and supports the assignment of *endo* to 17b.

Steric Course of Phosphoinositide-Specific Phospholipase C. As shown in Figure 2, the cIPs produced from the reactions catalyzed by the three PI-PLCs have the same δ³¹P as the *exo* isomer of cIPs. This was further confirmed by addition of the *endo* isomer and the *exo* isomer independently to the reaction mixture followed by ³¹P NMR analysis. Therefore, the stereochemical course of the conversion of PI to cIP catalyzed by PI-PLC was inversion in the configuration of phosphorus as shown in Scheme III.

DISCUSSION

PI-PLC specifically catalyzes hydrolysis of the *R*_p isomer of DPPsI, which corresponds to the *S*_p isomer of the phosphorothioate analogues of phosphatidylcholines. It is inter-

Scheme III: Steric Course of Formation of cIPs Catalyzed by PI-PLC




esting that PC-PLC and the three different PI-PLCs, which differ greatly in catalytic and structural properties, all have the same stereochemical requirement at phosphorus.

Scheme IV summarizes the six possible mechanisms for the formation of IP and cIP from DPPSI, along with the predicted stereochemical outcomes (assuming every single substitution at phosphorus is inversion, as has been the case in most known enzymatic reactions). Mechanisms A and B are parallel re-

actions (at the same active site) and are favored by some in the field (Dawson et al., 1971; Michell, 1975; Quinn, 1978; Majerus et al., 1986). Mechanism B differs from A in that a covalent enzyme-phosphoinositol intermediate has been formed. In mechanisms C and D cIP is first formed and then converted to IP by an enzyme-mediated process. Nonsynthetic conversion of cIP to IP can be ruled out since when cIP is subjected to chemical hydrolysis, both IP and 2-IP should be obtained, as has been demonstrated by Pizer and Ballou (1959). Mechanism C mimics the mechanism of ribonuclease A, but ribonuclease A does not release the cyclic intermediate. Mechanism D differs from C in that a covalent enzyme-phosphoinositol intermediate has been formed. It has been shown that both IP and cIP are released from the substrate simultaneously and there is no subsequent interconversion of cIP into IP or vice versa (Dawson et al., 1971; Allan & Michell, 1974; Lapetina & Michell, 1973; Michell, 1975; Quinn, 1978; Majerus et al., 1986). Therefore, these two mechanisms (C and D) seem less likely. Mechanisms E and F differ from C and D, respectively, in the order of formation of IP and cIP. These two mechanisms (E and F) are unlikely and can be ruled out because no ¹⁸O was incorporated into cIP

Scheme IV: Possible Mechanisms of PI-PLC






FIGURE 4: NOESY spectra of **17a** (A) and **17b** (B). The peaks labeled (a,4) in **17a** and (a,2) in **17b** represent the critical NOEs discussed in the text. The unlabeled cross peaks arise from the NOE between the benzyl CH₂ protons and various other protons.

when the reaction was carried out in [¹⁸O]water (Wilson et al., 1984, 1985). The observed inversion in the formation of cIPs rules out mechanisms B and D. The remaining possibilities are mechanisms A and C. Mechanism C is less likely as mentioned above. Furthermore, mechanism C would predict that IP is formed in much lower quantity than cIPs since there is one additional step in the formation of IP which almost certainly will be slowed down by sulfur substitution. Our observation that the ratio cIPs/IPs remains similar to that of IP/cIP for the two mammalian PI-PLCs strongly argues against mechanism C. Thus mechanism A remains as the only feasible mechanism.

Another point of interest is why the *B. cereus* PI-PLC gives only cIP as the product. Since the *B. cereus* enzyme does not require a divalent metal ion for catalysis, we speculate that the divalent metal ion in the mammalian PI-PLC could mediate the water attack to give IP in mechanism A. Whether this is the case or not, it is intriguing how the enzyme mediates two competing reactions at the active site, with the water molecule and the 2-OH group both occupying optimal positions for "in-line" attack.

ACKNOWLEDGMENTS

We are indebted to M. Angioli of Smith Kline & French

Laboratories, King of Prussia, PA, for purification of isozyme II of PI-PLC from guinea pig uterus and to Dr. C. Cottrell and Dr. C. Engelman of The Ohio State University for assistance in NMR measurements.

REFERENCES

- Allan, D., & Michell, R. H. (1974) *Biochem. J.* **142**, 591–597.
- Bennett, C. F., & Crooke, S. T. (1987) *J. Biol. Chem.* **262**, 13789–13797.
- Bentrude, W. G., & Tan, H.-W. (1976) *J. Am. Chem. Soc.* **98**, 1850–1859.
- Bentrude, W. G., & Setzer, W. N. (1987) in *Phosphorus-31 NMR Spectroscopy in Stereochemical Analysis* (Verkade, J. G., & Quin, L. D., Eds.) pp 365–389, VCH Publishers, Deerfield Beach, FL.
- Bentrude, W. G., Hargis, J. H., Nelson, A. J., Tae, B. M., Rusek, P. E., Tan, H.-W., & Wielesek, R. A. (1976) *J. Am. Chem. Soc.* **98**, 5348–5357.
- Berridge, M. J. (1986) in *Phosphoinositides and Receptor Mechanisms* (Putney, J. W., Ed.) Vol. 7 of *Receptor Biochemistry and Methodology* (Venter, J. C., & Harrison, L. C., Eds.) pp 25–45, Alan R. Liss, New York.
- Berridge, M. J. (1987) *Annu. Rev. Biochem.* **56**, 159–193.
- Billington, D. C., Baker, R., Kulagowski, J., & Mawer, I. M. (1987) *J. Chem. Soc., Chem. Commun.*, 314–316.
- Bruzik, K., & Tsai, M.-D. (1984) *J. Am. Chem. Soc.* **106**, 747–754.
- Bruzik, K., Gupte, S. M., & Tsai, M.-D. (1982) *J. Am. Chem. Soc.* **104**, 4682–4684.
- Bruzik, K., Jiang, R.-T., & Tsai, M.-D. (1983) *Biochemistry* **22**, 2478–2486.
- Bruzik, K. S. (1988) *J. Chem. Soc., Perkin Trans. 1*, 423–431.
- Bruzik, K. S., Salamonczyk, G., & Stec, W. J. (1986) *J. Org. Chem.* **51**, 2368–2370.
- Cerdan, S., Hansen, C. A., Johanson, R., Inubushi, T., & Williamson, J. (1986) *J. Biol. Chem.* **261**, 14676–14680.
- Corey, E. J., Pan, B.-C., Hua, D. H., & Deardorff, D. R. (1982a) *J. Am. Chem. Soc.* **104**, 6816–6818.
- Corey, E. J., Hua, D. H., Pan, B.-C., & Steitz, S. P. (1982b) *J. Am. Chem. Soc.* **104**, 6818–6820.
- Dawson, R. M., Freinkel, N., Jugalwala, F. B., & Clarke, N. (1971) *Biochem. J.* **122**, 605–607.
- Denney, D. Z., Chen, G. Y., & Denney, D. B. (1969) *J. Am. Chem. Soc.* **91**, 6838–6841.
- Garegg, P. J., Iversen, T., Johansson, R., & Lindberg, B. (1984) *Carbohydr. Res.* **130**, 322–326.
- Hauser, H., Guyer, W., Pascher, I., Skrabal, P., & Sundell, S. (1980) *Biochemistry* **19**, 366–373.
- Ikezawa, H., & Taguchi, R. (1986) *Tanpakushitsu Kakusan Koso (Japanese)* **31**, 455–462.
- Jensen, N. J., Tomer, K. B., & Gross, M. L. (1987) *Lipids* **22**, 480–489.
- Jiang, R.-T., Shyy, Y.-J., & Tsai, M.-D. (1984) *Biochemistry* **23**, 1661–1667.
- Jugalwala, F. B. (1985) in *Phospholipids in Nervous Tissues* (Eichberg, J., Ed.) pp 1–44, John Wiley & Sons, New York.
- Lapetina, E. G., & Michell, R. H. (1973) *Biochem. J.* **131**, 433–442.
- Lin, G. (1989) Stereochemistry and Mechanism of Phospholipase A₂ and Phosphatidylinositol-Specific Phospholipase C, Ph.D. Dissertation, The Ohio State University.
- Lin, G., & Tsai, M.-D. (1989) *J. Am. Chem. Soc.* **111**, 3099–3101.
- Loffredo, W. M., & Tsai, M.-D. (1990) *Bioorg. Chem.* (in press).
- Majerus, P. W., Connolly, T. M., Deckmyn, H., Ross, T. S.,

- Bross, T. E., Ishii, H., Bansal, V. S., & Wilson, D. B. (1986) *Science* 234, 1519-1526.
- Majerus, P. W., Connolly, T. M., Bansal, V. S., Inhorn, R. C., Ross, T. S., & Lips, D. L. (1988) *J. Biol. Chem.* 263, 3051-3054.
- McEven, W. C. (1965) *Top. Phosphorus Chem.* 2, 1-41.
- Michell, R. H. (1975) *Biochim. Biophys. Acta* 415, 81-147.
- Mikolajczyk, M., & Witczak, M. (1977) *J. Chem. Soc., Perkin Trans 1*, 2213-2222.
- Mikolajczyk, M., Witczak, M., Wieczorek, M., Bokij, N. G., & Struchkov, Y. T. (1976) *J. Chem. Soc., Perkin Trans. 1*, 371-377.
- Orr, G. A., Brewer, C. F., & Heney, G. (1982) *Biochemistry* 21, 3202-3206.
- Ozaki, S., Watanabe, Y., Ogasawara, T., Konodo, Y., Shiotani, N., Nishii, H., & Matsuki, T. (1986) *Tetrahedron Lett.* 27, 3157-3160.
- Pizer, F. L., & Ballou, C. E. (1959) *J. Am. Chem. Soc.* 81, 915-921.
- Potter, B. V. L., & Lowe, G. (1981) *Biochem. J.* 199, 693-698.
- Quinn, P. J. (1978) in *Cyclitols and phosphoinositides* (Wells, W. W., & Eisengerg, F., Eds.) Academic Press, New York.
- Schultz, C., Metschies, T., & Jastorff, B. (1988) *Tetrahedron Lett.* 29, 3919-3920.
- Shibata, T., Uzawa, J., Sugiura, Y., Hayashi, K., & Takizawa, T. (1984) *Chem. Phys. Lipids* 34, 107-113.
- Shukla, S. D. (1982) *Life Sci.* 30, 1323-1335.
- Stork, G., & Takahashi, T. (1977) *J. Am. Chem Soc.* 99, 1275-1276.
- Sundler, R., Alberts, A. W., & Vagelos, P. R. (1978) *J. Biol. Chem.* 253, 4175-4179.
- Tsai, T.-C., Hart, J., Jiang, R.-T., Bruzik, K., & Tsai, M.-D. (1985) *Biochemistry* 24, 3180-3188.
- Watanabe, Y., Ogasawara, T., Nakahira, H., Matsuki, T., & Ozaki, S. (1988) *Tetrahedron. Lett.* 29, 5259-5262.
- Wilson, D. B., Bross, T. E., Hofmann, S. L., & Majerus, P. W. (1984) *J. Biol. Chem.* 259, 11718-11724.
- Wilson, D. B., Bross, T. E., Sherman, W. R., Berger, R. A., & Majerus, P. W. (1985) *Proc. Natl. Acad. Sci. U.S.A.* 82, 4013-4017.